

Marta Barisa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1363482/publications.pdf>

Version: 2024-02-01

11
papers

339
citations

1307594

7
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

728
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Profiling lymphocyte interactions at the single-cell level by microfluidic cell pairing. Nature Communications, 2015, 6, 5940. | 12.8 | 148 |
| 2 | Antigen-specific B-cell receptor sensitizes B cells to infection by influenza virus. Nature, 2013, 503, 406-409. | 27.8 | 66 |
| 3 | Monoclonal Invariant NKT (iNKT) Cell Mice Reveal a Role for Both Tissue of Origin and the TCR in Development of iNKT Functional Subsets. Journal of Immunology, 2017, 199, 159-171. | 0.8 | 30 |
| 4 | Engineering $\gamma\delta$ T cells limits tonic signaling associated with chimeric antigen receptors. Science Signaling, 2019, 12, . | 3.6 | 29 |
| 5 | E. coli promotes human $\gamma\delta$ T cell transition from cytokine-producing bactericidal effectors to professional phagocytic killers in a TCR-dependent manner. Scientific Reports, 2017, 7, 2805. | 3.3 | 24 |
| 6 | A Simple and Robust Single-Step Method for CAR- $\gamma\delta$ T Cell Expansion and Transduction for Cancer Immunotherapy. Frontiers in Immunology, 2022, 13, . | 4.8 | 16 |
| 7 | Near-Infrared PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers: Challenges and potentials for human applications. Critical Reviews in Oncology/Hematology, 2021, 161, 103325. | 4.4 | 15 |
| 8 | Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction. Cancers, 2020, 12, 2326. | 3.7 | 6 |
| 9 | Payload Delivery: Engineering Immune Cells to Disrupt the Tumour Microenvironment. Cancers, 2021, 13, 6000. | 3.7 | 3 |
| 10 | Interplay between $\gamma\delta$ T-Cell Metabolism and Tumour Microenvironment Offers Opportunities for Therapeutic Intervention. Immunometabolism, 2021, 3, 210026. | 1.6 | 2 |
| 11 | Preclinical platforms to study therapeutic efficacy of human $\gamma\delta$ T cells for oncology indications. Clinical and Translational Discovery, 2022, 2, . | 0.5 | 0 |